Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men

Background: Antiretroviral chemoprophylaxis before exposure is a promising approach for the prevention of human immunodeficiency virus (HIV) acquisition.

Methods: We randomly assigned 2499 HIV-seronegative men or transgender women who have sex with men to receive a combination of two oral antiretroviral drugs, emtricitabine and tenofovir disoproxil fumarate (FTC-TDF), or placebo once daily. All subjects received HIV testing, risk-reduction counseling, condoms, and management of sexually transmitted infections.

Results: The study subjects were followed for 3324 person-years (median, 1.2 years; maximum, 2.8 years). Of these subjects, 10 were found to have been infected with HIV at enrollment, and 100 became infected during follow-up (36 in the FTC-TDF group and 64 in the placebo group), indicating a 44% reduction in the incidence of HIV (95% confidence interval, 15 to 63; P=0.005). In the FTC-TDF group, the study drug was detected in 22 of 43 of seronegative subjects (51%) and in 3 of 34 HIV-infected subjects (9%) (P<0.001). Nausea was reported more frequently during the first 4 weeks in the FTC-TDF group than in the placebo group (P<0.001). The two groups had similar rates of serious adverse events (P=0.57).

Conclusions: Oral FTC-TDF provided protection against the acquisition of HIV infection among the subjects. Detectable blood levels strongly correlated with the prophylactic effect. (Funded by the National Institutes of Health and the Bill and Melinda Gates Foundation; ClinicalTrials.gov number, NCT00458393.).

Citing Articles

Updates on HIV Pre-exposure Prophylaxis in Latin America: Available Drugs and Implementation Status.

Gonzales-Gavancho C, Araoz-Salinas J, Ramon Tapia R, Quispe-Vicuna C, Reategui-Garcia M, Rios-Garcia W Infez Med. 2025; 33(1):29-49.

PMID: 40071257 PMC: 11892447. DOI: 10.53854/liim-3301-4.

Joinpoint regression and age period cohort analysis of global and Chinese HIV incidence trends from 1990 to 2021.

Wu M, Hong C, Dou Z Sci Rep. 2025; 15(1):8153.

PMID: 40059237 PMC: 11891302. DOI: 10.1038/s41598-025-92882-0.

Pre-exposure Prophylaxis (PrEP) For Prevention of Human Immunodeficiency Virus: A Primary Practice Approach.

Sattar B, Beach R, Johnson P J Gen Intern Med. 2025; .

PMID: 40055286 DOI: 10.1007/s11606-025-09437-2.

Innovations for building implementation science capacity among researchers and policymakers: The Depth and Diffusion Model.

Bartels S, Hoang V, Giang L, Thu T, Dyk Q, Sripaipan T Glob Implement Res Appl. 2025; 4(3):272-285.

PMID: 40052002 PMC: 11884728. DOI: 10.1007/s43477-024-00121-x.

Recurrence of sexually transmitted infections is commonly found in a subpopulation of Austrian users of HIV pre-exposure prophylaxis.

Urban N, Neidhart T, Grabmeier-Pfistershammer K, Touzeau-Roemer V, Schmidt K, Strassl R Wien Klin Wochenschr. 2025; .

PMID: 40025206 DOI: 10.1007/s00508-025-02499-6.

References

Connor E, Sperling R, Gelber R, Kiselev P, Scott G, OSullivan M . Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994; 331(18):1173-80. DOI: 10.1056/NEJM199411033311801. View

Denton P, Estes J, Sun Z, Othieno F, Wei B, Wege A . Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. PLoS Med. 2008; 5(1):e16. PMC: 2194746. DOI: 10.1371/journal.pmed.0050016. View

Schechter M, do Lago R, Mendelsohn A, Moreira R, Moulton L, Harrison L . Behavioral impact, acceptability, and HIV incidence among homosexual men with access to postexposure chemoprophylaxis for HIV. J Acquir Immune Defic Syndr. 2004; 35(5):519-25. DOI: 10.1097/00126334-200404150-00010. View

Martin J, Roland M, Neilands T, Krone M, Bamberger J, Kohn R . Use of postexposure prophylaxis against HIV infection following sexual exposure does not lead to increases in high-risk behavior. AIDS. 2004; 18(5):787-92. DOI: 10.1097/00002030-200403260-00010. View

Donnell D, Baeten J, Kiarie J, Thomas K, Stevens W, Cohen C . Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet. 2010; 375(9731):2092-8. PMC: 2922041. DOI: 10.1016/S0140-6736(10)60705-2. View

Mimiaga M, Case P, Johnson C, Safren S, Mayer K . Preexposure antiretroviral prophylaxis attitudes in high-risk Boston area men who report having sex with men: limited knowledge and experience but potential for increased utilization after education. J Acquir Immune Defic Syndr. 2009; 50(1):77-83. PMC: 2659469. DOI: 10.1097/QAI.0b013e31818d5a27. View

H Gray R, Kigozi G, Serwadda D, Makumbi F, Watya S, Nalugoda F . Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet. 2007; 369(9562):657-66. DOI: 10.1016/S0140-6736(07)60313-4. View

Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A . Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med. 2005; 2(11):e298. PMC: 1262556. DOI: 10.1371/journal.pmed.0020298. View

van Griensven F, Thienkrua W, Sukwicha W, Wimonsate W, Chaikummao S, Varangrat A . Sex frequency and sex planning among men who have sex with men in Bangkok, Thailand: implications for pre- and post-exposure prophylaxis against HIV infection. J Int AIDS Soc. 2010; 13:13. PMC: 2873546. DOI: 10.1186/1758-2652-13-13. View

10.

Schacker T, Hughes J, Shea T, Coombs R, Corey L . Biological and virologic characteristics of primary HIV infection. Ann Intern Med. 1998; 128(8):613-20. DOI: 10.7326/0003-4819-128-8-199804150-00001. View

11.

Koblin B, Chesney M, Coates T . Effects of a behavioural intervention to reduce acquisition of HIV infection among men who have sex with men: the EXPLORE randomised controlled study. Lancet. 2004; 364(9428):41-50. DOI: 10.1016/S0140-6736(04)16588-4. View

12.

Baggaley R, White R, Boily M . HIV transmission risk through anal intercourse: systematic review, meta-analysis and implications for HIV prevention. Int J Epidemiol. 2010; 39(4):1048-63. PMC: 2929353. DOI: 10.1093/ije/dyq057. View

13.

Mayer K, Mimiaga M, Cohen D, Grasso C, Bill R, Van Derwarker R . Tenofovir DF plus lamivudine or emtricitabine for nonoccupational postexposure prophylaxis (NPEP) in a Boston Community Health Center. J Acquir Immune Defic Syndr. 2008; 47(4):494-9. DOI: 10.1097/QAI.0b013e318162afcb. View

14.

Liu A, Kittredge P, Vittinghoff E, Raymond H, Ahrens K, Matheson T . Limited knowledge and use of HIV post- and pre-exposure prophylaxis among gay and bisexual men. J Acquir Immune Defic Syndr. 2008; 47(2):241-7. View

15.

Peterson L, Taylor D, Roddy R, Belai G, Phillips P, Nanda K . Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trial. PLoS Clin Trials. 2007; 2(5):e27. PMC: 1876601. DOI: 10.1371/journal.pctr.0020027. View

16.

Gallant J, Winston J, DeJesus E, Pozniak A, Chen S, Cheng A . The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients. AIDS. 2008; 22(16):2155-63. DOI: 10.1097/QAD.0b013e3283112b8e. View

17.

Smith D, Grohskopf L, Black R, Auerbach J, Veronese F, Struble K . Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the U.S. Department of Health and Human Services. MMWR Recomm Rep. 2005; 54(RR-2):1-20. View

18.

Garcia-Lerma J, Otten R, Qari S, Jackson E, Cong M, Masciotra S . Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med. 2008; 5(2):e28. PMC: 2225435. DOI: 10.1371/journal.pmed.0050028. View

19.

Tsai C, Follis K, Sabo A, Beck T, Grant R, Bischofberger N . Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science. 1995; 270(5239):1197-9. DOI: 10.1126/science.270.5239.1197. View

20.

van Griensven F, van Wijngaarden J, Baral S, Grulich A . The global epidemic of HIV infection among men who have sex with men. Curr Opin HIV AIDS. 2009; 4(4):300-7. DOI: 10.1097/COH.0b013e32832c3bb3. View